ESR1 and breast cancer: Collectively, our study indicates that degrading ER in an endocrine resistant, estrogen independent, ER mutant model can provide a therapeutic benefit and suggests that fulvestrant may have an important role in the treatment of ER positive breast cancer with acquired ER mutations.